2
Supplemental Figure 1 -531 +60 8 CpG island A MCF10A MCF10AT MCF10CA1acl.1 MDA-MB231 MDA-MB435 TIS TIS TIS TIS TIS

Supplemental Figure 1

Embed Size (px)

DESCRIPTION

MCF10A. TIS. -531. +608. MCF10AT. CpG island A. TIS. MCF10CA1acl.1. TIS. MDA-MB231. TIS. MDA-MB435. TIS. Supplemental Figure 1. Supplemental Figure 2. - PowerPoint PPT Presentation

Citation preview

Page 1: Supplemental Figure 1

Supplemental Figure 1

-531 +608

CpG island A

MCF10A

MCF10AT

MCF10CA1acl.1

MDA-MB231

MDA-MB435

TIS

TIS

TIS

TIS

TIS

Page 2: Supplemental Figure 1

10A

10A-0

.05

10AT

10AT-

0.05

10CA

10CA-0

.05

231

231-

0.05 43

5

435-

0.05

0.5

5

Fo

ld c

han

ge

in 3

GN

T1

mR

NA

leve

lsin

res

po

nse

to

5-d

eoxy

-2'-

azac

ytid

ine

Supplemental Figure 2


Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures

Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures

Documents
Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

Documents
Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Documents
Supplemental figure 1: Dapul_304363

Supplemental figure 1: Dapul_304363

Documents
1. Supplemental Figure 1 - International Journal of ... · Supplemental Figure 1 2. Supplemental Figure 2 3. Supplemental Figure 3 4. Supplemental Figure 4 5. Supplemental Figure

1. Supplemental Figure 1 - International Journal of ... · Supplemental Figure 1 2. Supplemental Figure 2 3. Supplemental Figure 3 4. Supplemental Figure 4 5. Supplemental Figure

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Documents
SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

Documents
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

Documents
Supplemental Digital Content Supplemental Figure 1

Supplemental Digital Content Supplemental Figure 1

Documents
Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B

Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B

Documents
Supplemental Figure Legends: Supplemental Figure S1 ...genesdev.cshlp.org/content/suppl/2014/07/11/gad... · Supplemental Figure Legends: Supplemental Figure S1 Vernalization response

Supplemental Figure Legends: Supplemental Figure S1 ...genesdev.cshlp.org/content/suppl/2014/07/11/gad... · Supplemental Figure Legends: Supplemental Figure S1 Vernalization response

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
List of Supplemental Digital Content Supplemental Figure 1

List of Supplemental Digital Content Supplemental Figure 1

Documents
Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Supplemental materials 2 Supplemental Figure 1.Antibody ...dm5migu4zj3pb.cloudfront.net/manuscripts/66000/66824/JCI66824sd.pdf · Supplemental Figure . PRL5 -3 is expressed at higher

Documents
Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Documents
Supplemental data: Supplemental Figure 1. Sequence of

Supplemental data: Supplemental Figure 1. Sequence of

Documents
Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2

Supplemental Figure 1. 1000 cells/ well DLD-1 ALDH+/CD133+ DLD-1 ALDH- /CD133- Supplemental Figure 2

Documents
Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Documents
Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

Documents
Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Documents
SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z

Documents
Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Documents
Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,

Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,

Documents
BolteusBordey Supplemental Figure 1

BolteusBordey Supplemental Figure 1

Documents
Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Documents